This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition
2026-02-19 17:23:28 ET
On February 17, 2026, Connecticut-based Braidwell disclosed a new position in Centessa Pharmaceuticals (NASDAQ:CNTA) , acquiring 2,188,320 shares in an estimated $54.73 million trade.
In a new U.S. Securities and Exchange Commission (SEC) filing released February 17, 2026 ( link ), Braidwell disclosed the purchase of 2,188,320 shares of Centessa. The net position change for the quarter was $54.73 million, reflecting the new holding’s quarter-end valuation.
Centessa is a clinical-stage biotechnology company headquartered in the United Kingdom. The company leverages a diversified pipeline approach, advancing multiple candidates across nephrology, hematology, immunology, and rare disease indications. Its strategy emphasizes rapid clinical development and potential first-in-class therapies, positioning Centessa to address significant unmet medical needs in specialty care markets.
NASDAQ: CNTA
CNTA Trading
5.75% G/L:
$26.95 Last:
692,637 Volume:
$26.16 Open:
